Induction of Fetal Hemoglobin by Introducing Natural Hereditary Persistence of Fetal Hemoglobin Mutations in the γ-Globin Gene Promoters for Genome Editing Therapies for β-Thalassemia

Reactivation of gamma-globin expression is a promising therapeutic approach for beta-hemoglobinopathies. Here, we propose a novel Cas9/AAV6-mediated genome editing strategy for the treatment of beta-thalassemia: Natural HPFH mutations -113A > G, -114C > T, -117G>A, -175T > C, -195C > G, and -198T > C were introduced by homologous recombination following disruption of BCL11A binding sites in HBG1/HBG2 promoters. Precise on-target editing and significantly increased gamma-globin expression during erythroid differentiation were observed in both HUDEP-2 cells and primary HSPCs from beta-thalassemia major patients. Moreover, edited HSPCs maintained the capacity for long-term hematopoietic reconstitution in B-NDG hTHPO mice. This study provides evidence of the effectiveness of introducing naturally occurring HPFH mutations as a genetic therapy for beta-thalassemia.

Automated summary

This study proposes a novel Cas9/AAV6-mediated genome editing strategy for treating beta-thalassemia. By introducing naturally occurring HPFH mutations and disrupting BCL11A binding sites in HBG1/HBG2 promoters, precise on-target editing and significantly increased gamma-globin expression were observed.